Histogenics to Present at 7th Annual New York Stem Cell Summit

WALTHAM, Mass.--(BUSINESS WIRE)--

Histogenics Corporation, a privately held regenerative medicine company, today announced that the Company will present at the 7th Annual New York Stem Cell Summit on February 21st at Bridgewaters New York City. Kirk Andriano, Ph.D., Vice President of Research and Development for Histogenics, will speak about current and future cell therapies being developed by the Company as it works toward commercialization. Lead candidates include NeoCart®, an autologous bioengineered neocartilage grown outside the body using the patient’s own cells for the regeneration of cartilage lesions, and VeriCart™, a three-dimensional cartilage matrix designed to stimulate cartilage repair in a simple, one-step procedure. NeoCart recently entered a Phase 3 clinical trial after reporting positive Phase 2 data, in which all primary endpoints were met and a favorable safety profile was demonstrated.

Dr. Andriano earned his BS in chemistry and biology from Utah State University and his MS and Ph.D. in bioengineering from the University of Utah. Prior to his work at Histogenics, he was the Chief Technology Officer for ProChon Biotech, Ltd. which was acquired by Histogenics in May 2011.

About Histogenics

Histogenics is a leading regenerative medicine company that combines cell therapy and tissue engineering technologies to develop highly innovative products for tissue repair and regeneration. In May of 2011, Histogenics acquired Israeli cell-therapy company ProChon BioTech. Histogenics’ flagship products focus on the treatment of active patients suffering from articular cartilage derived pain and immobility. The Company takes an interdisciplinary approach to engineering neocartilage that looks, acts and lasts like hyaline cartilage. It is developing new treatments for sports injuries and other orthopaedic conditions, where demand is growing for long-term alternatives to joint replacement. Histogenics has successfully completed Phase 1 and Phase 2 clinical trials of its NeoCart autologous tissue implant and is currently in a Phase 3 IND clinical study. Based in Waltham, Massachusetts, the company is privately held. For more information, visit http://www.histogenics.com.

See original here:
Histogenics to Present at 7th Annual New York Stem Cell Summit